Respiratory medication used in COPD patients from seven Latin American countries: the LASSYC study
Alejandro Casas,1 Maria Montes de Oca,2 Ana MB Menezes,3 Fernando C Wehrmeister,3 Maria Victorina Lopez Varela,4 Laura Mendoza,5 Larissa Ramírez,6 Marc Miravitlles7 On behalf of the LASSYC team 1Fundación Neumológica Colombiana, Universidad del Rosario, Bogot&a...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2018-05-01
|
| Series: | International Journal of COPD |
| Subjects: | |
| Online Access: | https://www.dovepress.com/respiratory-medication-used-in-copd-patients-from-seven-latin-american-peer-reviewed-article-COPD |
| _version_ | 1828175402985586688 |
|---|---|
| author | Casas A Montes de Oca M Menezes AMB Wehrmeister FC Lopez Varela MV Mendoza L Ramírez L Miravitlles M |
| author_facet | Casas A Montes de Oca M Menezes AMB Wehrmeister FC Lopez Varela MV Mendoza L Ramírez L Miravitlles M |
| author_sort | Casas A |
| collection | DOAJ |
| description | Alejandro Casas,1 Maria Montes de Oca,2 Ana MB Menezes,3 Fernando C Wehrmeister,3 Maria Victorina Lopez Varela,4 Laura Mendoza,5 Larissa Ramírez,6 Marc Miravitlles7 On behalf of the LASSYC team 1Fundación Neumológica Colombiana, Universidad del Rosario, Bogotá, Colombia; 2Universidad Central de Venezuela, Caracas, Venezuela; 3Federal University of Pelotas, Pelotas, Brazil; 4Universidad de la República, Montevideo, Uruguay; 5Hospital Clínico Universidad de Chile, Santiago de Chile, Chile; 6AstraZeneca, San José, Costa Rica; 7Department of Pneumology, Hospital Universitari Vall d’Hebron, CIBER de Enfermedades Respiratorias (CIBERES), Barcelona, Spain Background: Limited information is available regarding medication use in COPD patients from Latin America. This study evaluated the type of medication used and the adherence to different inhaled treatments in stable COPD patients from the Latin American region.Methods: This was an observational, cross-sectional, multinational, and multicenter study in COPD patients attended by specialist doctors from seven Latin American countries. Adherence to inhaled therapy was assessed using the Test of Adherence to Inhalers (TAI) questionnaire. The type of medication was assessed as: short-acting β-agonist (SABA) or short-acting muscarinic antagonist (SAMA) only, long-acting muscarinic antagonist (LAMA), long-acting β-agonist (LABA), LABA/LAMA, inhaled corticosteroid (ICS), ICS/LABA, ICS/LAMA/LABA, or other.Results: In total, 795 patients were included (59.6% male), with a mean age of 69.5±8.7 years and post-bronchodilator FEV1 of 50.0%±18.6%. The ICS/LAMA/LABA (32.9%) and ICS/LABA (27.7%) combinations were the most common medications used, followed by LABA/LAMA (11.3%), SABA or SAMA (7.9%), LABA (6.4%), LAMA (5.8%), and ICS (4.3%). The types of medication most commonly used in each Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2013 category were ICS/LABA (A: 32.7%; B: 19.8%; C: 25.7%; D: 28.2%) and ICS/LAMA/LABA (A: 17.3%; B: 30.2%; C: 33%; D: 41.1%). The use of long-acting bronchodilators showed the highest adherence (good or high adherence >50%) according to the TAI questionnaire.Conclusion: COPD management in specialist practice in Latin America does not follow the current guideline recommendations and there is an overuse of ICSs in patients with COPD from this region. Treatment regimens including the use of long-acting bronchodilators are associated with the highest adherence. Keywords: adherence, inhaled therapy, COPD, Latin America |
| first_indexed | 2024-04-12T04:27:49Z |
| format | Article |
| id | doaj.art-8ed796335ed544aa9bcafa727381a5c5 |
| institution | Directory Open Access Journal |
| issn | 1178-2005 |
| language | English |
| last_indexed | 2024-04-12T04:27:49Z |
| publishDate | 2018-05-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | International Journal of COPD |
| spelling | doaj.art-8ed796335ed544aa9bcafa727381a5c52022-12-22T03:48:02ZengDove Medical PressInternational Journal of COPD1178-20052018-05-01Volume 131545155638257Respiratory medication used in COPD patients from seven Latin American countries: the LASSYC studyCasas AMontes de Oca MMenezes AMBWehrmeister FCLopez Varela MVMendoza LRamírez LMiravitlles MAlejandro Casas,1 Maria Montes de Oca,2 Ana MB Menezes,3 Fernando C Wehrmeister,3 Maria Victorina Lopez Varela,4 Laura Mendoza,5 Larissa Ramírez,6 Marc Miravitlles7 On behalf of the LASSYC team 1Fundación Neumológica Colombiana, Universidad del Rosario, Bogotá, Colombia; 2Universidad Central de Venezuela, Caracas, Venezuela; 3Federal University of Pelotas, Pelotas, Brazil; 4Universidad de la República, Montevideo, Uruguay; 5Hospital Clínico Universidad de Chile, Santiago de Chile, Chile; 6AstraZeneca, San José, Costa Rica; 7Department of Pneumology, Hospital Universitari Vall d’Hebron, CIBER de Enfermedades Respiratorias (CIBERES), Barcelona, Spain Background: Limited information is available regarding medication use in COPD patients from Latin America. This study evaluated the type of medication used and the adherence to different inhaled treatments in stable COPD patients from the Latin American region.Methods: This was an observational, cross-sectional, multinational, and multicenter study in COPD patients attended by specialist doctors from seven Latin American countries. Adherence to inhaled therapy was assessed using the Test of Adherence to Inhalers (TAI) questionnaire. The type of medication was assessed as: short-acting β-agonist (SABA) or short-acting muscarinic antagonist (SAMA) only, long-acting muscarinic antagonist (LAMA), long-acting β-agonist (LABA), LABA/LAMA, inhaled corticosteroid (ICS), ICS/LABA, ICS/LAMA/LABA, or other.Results: In total, 795 patients were included (59.6% male), with a mean age of 69.5±8.7 years and post-bronchodilator FEV1 of 50.0%±18.6%. The ICS/LAMA/LABA (32.9%) and ICS/LABA (27.7%) combinations were the most common medications used, followed by LABA/LAMA (11.3%), SABA or SAMA (7.9%), LABA (6.4%), LAMA (5.8%), and ICS (4.3%). The types of medication most commonly used in each Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2013 category were ICS/LABA (A: 32.7%; B: 19.8%; C: 25.7%; D: 28.2%) and ICS/LAMA/LABA (A: 17.3%; B: 30.2%; C: 33%; D: 41.1%). The use of long-acting bronchodilators showed the highest adherence (good or high adherence >50%) according to the TAI questionnaire.Conclusion: COPD management in specialist practice in Latin America does not follow the current guideline recommendations and there is an overuse of ICSs in patients with COPD from this region. Treatment regimens including the use of long-acting bronchodilators are associated with the highest adherence. Keywords: adherence, inhaled therapy, COPD, Latin Americahttps://www.dovepress.com/respiratory-medication-used-in-copd-patients-from-seven-latin-american-peer-reviewed-article-COPDAdherenceinhaled therapyCOPDLatin America. |
| spellingShingle | Casas A Montes de Oca M Menezes AMB Wehrmeister FC Lopez Varela MV Mendoza L Ramírez L Miravitlles M Respiratory medication used in COPD patients from seven Latin American countries: the LASSYC study International Journal of COPD Adherence inhaled therapy COPD Latin America. |
| title | Respiratory medication used in COPD patients from seven Latin American countries: the LASSYC study |
| title_full | Respiratory medication used in COPD patients from seven Latin American countries: the LASSYC study |
| title_fullStr | Respiratory medication used in COPD patients from seven Latin American countries: the LASSYC study |
| title_full_unstemmed | Respiratory medication used in COPD patients from seven Latin American countries: the LASSYC study |
| title_short | Respiratory medication used in COPD patients from seven Latin American countries: the LASSYC study |
| title_sort | respiratory medication used in copd patients from seven latin american countries the lassyc study |
| topic | Adherence inhaled therapy COPD Latin America. |
| url | https://www.dovepress.com/respiratory-medication-used-in-copd-patients-from-seven-latin-american-peer-reviewed-article-COPD |
| work_keys_str_mv | AT casasa respiratorymedicationusedincopdpatientsfromsevenlatinamericancountriesthelassycstudy AT montesdeocam respiratorymedicationusedincopdpatientsfromsevenlatinamericancountriesthelassycstudy AT menezesamb respiratorymedicationusedincopdpatientsfromsevenlatinamericancountriesthelassycstudy AT wehrmeisterfc respiratorymedicationusedincopdpatientsfromsevenlatinamericancountriesthelassycstudy AT lopezvarelamv respiratorymedicationusedincopdpatientsfromsevenlatinamericancountriesthelassycstudy AT mendozal respiratorymedicationusedincopdpatientsfromsevenlatinamericancountriesthelassycstudy AT ramirezl respiratorymedicationusedincopdpatientsfromsevenlatinamericancountriesthelassycstudy AT miravitllesm respiratorymedicationusedincopdpatientsfromsevenlatinamericancountriesthelassycstudy |